RTU

Nexus Pharmaceuticals, Inc. Announces Launch of Emerphed™ (ephedrine sulfate) RTU Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)

Retrieved on: 
Friday, June 26, 2020
Medical Supplies, Health, Hospitals, Surgery, General Health, Pharmaceutical, Drugs, RTT, Decongestants, Norepinephrine releasing agents, Ephedrine, Traditional Chinese medicine, RTU, Emerphed, Nexus Pharmaceuticals, Inc.

Nexus Pharmaceuticals announced today that it has launched its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial.

Key Points: 
  • Nexus Pharmaceuticals announced today that it has launched its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial.
  • With no need for compounding, diluting, or mixing, Emerphed saves valuable staff time while also reducing the potential for preparation error and waste.
  • View the full release here: https://www.businesswire.com/news/home/20200626005500/en/
    Emerphed (ephedrine sulfate) RTU injection vial and carton (Photo: Business Wire).
  • Emerphed will be available in a ready-to-use 10 mL vial that does not require further dilution.

Transformative Wave Receives Industry Award for Commitment to High Efficiency Rooftop-Unit (RTU) Best Practices

Retrieved on: 
Tuesday, April 30, 2019
Building engineering, Building biology, Heating, ventilation, and air conditioning, RTU

AURORA, Colo., April 30, 2019 /PRNewswire-PRWeb/ --Transformative Wave, a leading innovator in HVAC energy efficiency based in Kent, Washington, has been recognized for its demonstrated commitment to high efficiency roof-top unit (RTU) best practices by the Better Building Alliance's Advanced Rooftop-Unit Campaign.

Key Points: 
  • AURORA, Colo., April 30, 2019 /PRNewswire-PRWeb/ --Transformative Wave, a leading innovator in HVAC energy efficiency based in Kent, Washington, has been recognized for its demonstrated commitment to high efficiency roof-top unit (RTU) best practices by the Better Building Alliance's Advanced Rooftop-Unit Campaign.
  • Transformative Wave was presented the award at the annual Professional Retail Store Maintenance Conference (PRSM) held today in Aurora, Colorado.
  • Transformative Wave created CATALYST, a complete HVAC energy efficiency retrofit kit for constant volume systems already in place and one of the top advanced RTU control (ARC) technologies on the market today.
  • "Transformative Wave is honored to receive the award and proud to partner with H&M as it works to reduce energy usage and costs," said Danny Miller, president of Transformative Wave.

Xellia Pharmaceuticals Receives US FDA Approval for Premixed Vancomycin Injection

Retrieved on: 
Tuesday, February 19, 2019
Health, Biotechnology, Infectious diseases, Medical devices, Pharmaceutical, FDA, Chemistry, Physical sciences, Food and Drug Administration, RTT, Health, MedWatch, Eli Lilly and Company, Vancomycin, RTU

Xellia Pharmaceuticals (Xellia), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has received U.S. Food and Drug Administration (FDA) approval for Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag in the United States market.

Key Points: 
  • Xellia Pharmaceuticals (Xellia), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has received U.S. Food and Drug Administration (FDA) approval for Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag in the United States market.
  • This first approval is a significant milestone for Xellia and an important validation of our strategy, said Carl-ke Carlsson, Xellias CEO.
  • Vancomycin Injection, Ready to use (RTU) is a proprietary formulation of vancomycin, provided as a premixed solution in single-dose flexible bags, stable at room temperature (up to 25 C) for 16 months.
  • (6.1)
    To report SUSPECTED ADVERSE REACTIONS, contact Xellia Pharmaceuticals USA, LLC at 1-833-295-6953 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Pre-Sterilized / Ready-to-Use Primary Packaging: Focus on Cartridges, Syringes and Vials, 2018-2030

Retrieved on: 
Tuesday, October 30, 2018
RTU

It offers a high-level view on the current state of the market of RTU primary packaging components and its likely evolution in the long term.

Key Points: 
  • It offers a high-level view on the current state of the market of RTU primary packaging components and its likely evolution in the long term.
  • Chapter 4 provides a comprehensive review of the current market landscape of RTU primary packaging components and the associated handling equipment.
  • Chapter 5 includes detailed profiles of active players that are involved in providing packaging components in the RTU format.
  • Owing to the rise in personalized therapeutics, RTU syringes are anticipated to witness the highest growth rate over the forecasted period.